Pharmaust Limited (AU:PAA) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmAust Limited reports a transformative quarter, focusing on neurodegenerative diseases and strengthening its leadership. The company’s drug monepantel has been granted Orphan Drug Designation by the US FDA and has shown promising survival data in ALS treatment studies. With a successful capital raise of $17.8 million, PharmAust is well-positioned to advance its ALS therapy.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.